Loading...
A growing awareness of the persistence of attention deficit hyperactivity disorder (ADHD) in adults has fueled interest in pharmacotherapeutic therapies. Stimulants, although effective, have side effects and abuse potential. Antidepressants are safer but less effective. Open trials in children suggest that guanfacine, the clonidine-like α2 adrenergic receptor agonist, may improve ADHD symptoms, but there are neither controlled studies nor reports of its effects in adults. Researchers in this double-blind, crossover trial compared the efficacy of gradually titrated dextroamphetamine (mean dose, 10 mg), guanfacine (mean dose, 1 mg), and placebo given once in the morning for 2 weeks (with 4-day washouts) in 17 ADHD adults aged 21 to 52 in a so…